Myriad to Announce Fiscal First-Quarter 2018 Financial Results on November 7, 2017
October 24 2017 - 4:05PM
Myriad Genetics, Inc. (NASDAQ: MYGN) today announced that it will
hold its fiscal first-quarter 2018 sales and earnings conference
call with investors and analysts at 4:30 p.m. ET on Tuesday,
November 7, 2017. During the call, Mark C. Capone, president
and CEO and Bryan Riggsbee, CFO, will provide an overview of
Myriad’s financial performance for the fiscal first-quarter and
provide a business update.
To listen to the call, interested parties in the United States
may dial 800-701-6414 or +1 303-223-4376 for international
callers. All callers will be asked to reference reservation
number 21859999. The conference call also will be available
through a live webcast and a slide presentation pertaining to the
earnings call will also be available under the investor section of
our website at www.myriad.com. A replay of the call will be
available two hours after the end of the call for seven days and
may be accessed by dialing 800-633-8284 within the United States or
+1 402-977-9140 for international callers and entering reservation
number 21859999.
About Myriad GeneticsMyriad Genetics Inc., is a
leading personalized medicine company dedicated to being a trusted
advisor transforming patient lives worldwide with pioneering
molecular diagnostics. Myriad discovers and commercializes
molecular diagnostic tests that: determine the risk of developing
disease, accurately diagnose disease, assess the risk of disease
progression, and guide treatment decisions across six major medical
specialties where molecular diagnostics can significantly improve
patient care and lower healthcare costs. Myriad is focused on
five strategic imperatives: stabilizing hereditary cancer
revenue, growing new product volume, expanding reimbursement
coverage for new products, increasing RNA kit revenue
internationally and improving profitability with Elevate
2020. For more information on how Myriad is making a
difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer,
myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx,
myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore and
Prolaris are trademarks or registered trademarks of Myriad
Genetics, Inc. or its wholly owned subsidiaries in the United
States and foreign countries. MYGN-F, MYGN-G.
Media Contact:
|
Ron Rogers
|
Investor Contact:
|
Scott Gleason |
|
(801) 584-3065 |
|
(801) 584-1143 |
|
rrogers@myriad.com |
|
sgleason@myriad.com |
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2023 to Apr 2024